Zhitong Finance App News, Yuheng Pharmaceutical (002437.SZ) issued an announcement and the company signed a “Technology Transfer (Patent) Contract” with Capital Medical University. According to the “Technology Transfer Contract” agreement, the company plans to acquire the patent for “A Marker and Application of Calcium Overload Induces Neuronal Death” at a transaction price of RMB 11.15 million.

According to the announcement, treatment with existing drugs focuses on lowering intraocular pressure (IOP), but some patients continue to worsen to blindness even after eye pressure is controlled — the core pathology “progressive death of retinal ganglion cells (RGC)” has lacked effective intervention for a long time. The “marker of calcium overload-mediated neuron death” involved in this project is a gene therapy to be developed to target TLK2, which is expected to break into the unmet clinical need for “RGC neuroprotection independent of eye pressure reduction.”

The TLK2 glaucoma axis mechanism involved in this project is the first in the world. Unlike existing neuroprotection routes under development, it has strong mechanism differentiation, and theoretically has the potential for one-time administration and long-term expression, and has certain R&D value and potential commercialization prospects.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.